| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_894b3d308c46d0a1634a03368a791b38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc98e76b4292320524162fe2dab0d7ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57017561f5c7acc9f483f790dfab09eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05767503a3be483ffe2952a2d8ff8d6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2011-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d74b59f698873da9b72ff9cb878aa70c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c12bdfdf5414c34a4f8f3bf33c1559c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f2bd80b40f3982ad0e6651a2670b891 |
| publicationDate |
2012-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012083004-A2 |
| titleOfInvention |
Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions |
| abstract |
The present invention provides methods for evaluating or monitoring the efficacy of a therapeutic intervention for treating a cardiac disorder. Such methods comprise measuring or detecting the level of at least one miRNA in a biological sample from a patient receiving the therapeutic intervention and comparing the level to the level of said at least one miRNA in a control sample, wherein the measured level of said at least one miRNA is indicative of the therapeutic efficacy of the therapeutic intervention. Methods of predicting or assessing the severity or progression of heart failure in a patient by measuring one or more miRNAs in a biological sample from the patient are also disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3034623-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107858419-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016177776-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016097118-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015066611-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103290116-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013093870-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4035659-A1 |
| priorityDate |
2010-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |